FY2025 EPS Estimates for Oncobiologics Increased by Analyst

Key Points

• HC Wainwright raised Oncobiologics' FY2025 earnings per share forecast from ($2.33) to ($1.96), signaling improved expectations for the company's financial performance.
• The firm reported a loss of ($0.44) EPS for the last quarter, missing consensus estimates by ($0.02), with total revenue of $1.51 million.
• Oncobiologics stock currently has an average rating of "Moderate Buy" with an average target price of $9.60 from analysts.

Oncobiologics, Inc. (NASDAQ:OTLK - Free Report) - Research analysts at HC Wainwright lifted their FY2025 EPS estimates for shares of Oncobiologics in a report issued on Monday, August 18th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($1.96) per share for the year, up from their prior estimate of ($2.33). The consensus estimate for Oncobiologics' current full-year earnings is ($2.27) per share. HC Wainwright also issued estimates for Oncobiologics' Q4 2025 earnings at ($0.23) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.11) EPS, FY2028 earnings at $0.28 EPS and FY2029 earnings at $0.53 EPS.

Other equities analysts have also issued research reports about the stock. Chardan Capital reiterated a "neutral" rating and issued a $3.00 price objective on shares of Oncobiologics in a report on Friday, August 15th. Ascendiant Capital Markets cut their price objective on shares of Oncobiologics from $24.00 to $21.00 and set a "buy" rating on the stock in a report on Friday, June 6th. Finally, Guggenheim reiterated a "buy" rating on shares of Oncobiologics in a report on Tuesday, May 20th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Oncobiologics has an average rating of "Moderate Buy" and a consensus price target of $9.60.

Oncobiologics Price Performance

NASDAQ OTLK traded up $0.1470 on Wednesday, reaching $2.8270. The company had a trading volume of 3,612,011 shares, compared to its average volume of 842,281. Oncobiologics has a 1 year low of $0.87 and a 1 year high of $8.32. The firm has a market capitalization of $125.58 million, a PE ratio of -4.94 and a beta of 0.26. The firm has a 50-day moving average of $2.01 and a 200-day moving average of $1.71.

Oncobiologics (NASDAQ:OTLK - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.02). The business had revenue of $1.51 million during the quarter, compared to analysts' expectations of $1.66 million.

Hedge Funds Weigh In On Oncobiologics

Several large investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its stake in Oncobiologics by 865.2% in the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company's stock valued at $39,000 after buying an additional 21,941 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company's stock valued at $126,000 after buying an additional 44,063 shares during the last quarter. AQR Capital Management LLC lifted its stake in Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company's stock valued at $103,000 after buying an additional 25,351 shares during the last quarter. Jane Street Group LLC lifted its stake in Oncobiologics by 133.9% in the fourth quarter. Jane Street Group LLC now owns 26,218 shares of the company's stock valued at $50,000 after buying an additional 15,008 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Oncobiologics in the fourth quarter valued at $246,000. 11.20% of the stock is currently owned by institutional investors.

About Oncobiologics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.